3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

Iveson, Timothy; Boyd, Kathleen A; Kerr, Rachel S; Robles-Zurita, Jose; Saunders, Mark P; Briggs, Andrew H; Cassidy, Jim; Hollander, Niels Henrik; Tabernero, Josep; Haydon, Andrew; +27 more... Glimelius, Bengt; Harkin, Andrea; Allan, Karen; McQueen, John; Pearson, Sarah; Waterston, Ashita; Medley, Louise; Wilson, Charles; Ellis, Richard; Essapen, Sharadah; Dhadda, Amandeep S; Harrison, Mark; Falk, Stephen; Raouf, Sherif; Rees, Charlotte; Olesen, Rene K; Propper, David; Bridgewater, John; Azzabi, Ashraf; Farrugia, David; Webb, Andrew; Cunningham, David; Hickish, Tamas; Weaver, Andrew; Gollins, Simon; Wasan, Harpreet; Paul, James; (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health technology assessment, 23 (64). pp. 1-88. ISSN 1366-5278 DOI: https://doi.org/10.3310/hta23640

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.3310/hta23640

Abstract

Share

Download

Filename: 3031223.pdf

Licence: Copyright the publishers

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar